Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 11/2017

01-11-2017 | Original Research Article

Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS2 Score ≥ 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?

Authors: Séverine Henrard, Caroline Vandenabeele, Sophie Marien, Benoit Boland, Olivia Dalleur

Published in: Drugs & Aging | Issue 11/2017

Login to get access

Abstract

Objective

Our objectives were to (1) describe the evolution of the underuse of anticoagulants in older people with atrial fibrillation (AF) and a CHADS2 score ≥ 2 since direct oral anticoagulants (DOACs) were introduced to the market and (2) describe factors associated with this underuse.

Methods

We conducted a retrospective cross-sectional study including geriatric patients admitted during the pre-DOAC (2008–2011) and post-DOAC (2013–2015) periods in an academic hospital in Belgium. Five inclusion criteria were met: age ≥ 75 years, diagnosis of AF, indication for anticoagulation (CHADS2 score ≥ 2), risk of functional decline (Identification of Seniors At Risk [ISAR] score ≥ 2), and comprehensive geriatric assessment. The use of anticoagulants and antiplatelets at home before admission was recorded. Risks of stroke and bleeding were calculated using CHADS2 and HEMORR2HAGES scores, respectively. Three different logistic regression models were performed to describe the evolution of and factors associated with the underuse of anticoagulants after DOAC marketing.

Results

Anticoagulant underuse, present in 209 of 614 (34%) geriatric patients with AF, was lower in patients with a history of stroke (28.5%) or congestive heart failure (26.9%) but higher in those receiving antiplatelets (56.2%) and in older individuals. Anticoagulant underuse decreased significantly from the pre-DOAC (37.3%) to the post-DOAC (29.7%) era, as shown by two analyses using propensity scores.

Conclusion

In older patients with AF, anticoagulant underuse was mainly associated with antiplatelet use. Anticoagulant underuse and antiplatelet use have both decreased since DOAC marketing. Underuse of anticoagulants was still a concern for three in ten geriatric patients with AF at high risk of stroke (CHADS2 score ≥ 2).
Appendix
Available only for authorised users
Literature
1.
Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38(4):1231–66.CrossRefPubMed
2.
Fuchs P, Vogel T, Lang PO. Anticoagulation in the aged patient with atrial fibrillation: what are prescribing cardiologists, geriatricians and general practitioners? Rev Med Interne. 2015;36(8):509–15.CrossRefPubMed
3.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.CrossRefPubMed
4.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.CrossRefPubMed
5.
Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS. Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med. 2012;271(1):15–24.CrossRefPubMed
6.
Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2013;126(4):289–96.CrossRefPubMed
7.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.CrossRefPubMed
8.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRefPubMed
9.
Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9.CrossRefPubMed
10.
Monte S, Macchia A, Pellegrini F, Romero M, Lepore V, D’Ettorre A, et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J. 2006;27(18):2217–23.CrossRefPubMed
11.
De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging. 2010;27(10):807–13.CrossRefPubMed
12.
Maes F, Dalleur O, Henrard S, Wouters D, Scavee C, Spinewine A, et al. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? Clin Interv Aging. 2014;9:1091–9.PubMedPubMedCentral
13.
Denoel P, Vanderstraeten J, Mols P, Pepersack T. Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly? J Aging Res. 2014;2014:693740.CrossRefPubMedPubMedCentral
14.
Granziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc. 2015;16(5):358–64.CrossRefPubMed
15.
Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med. 2003;163(13):1580–6.CrossRefPubMed
16.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMed
17.
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.CrossRefPubMed
18.
Suarez Fernandez C, Formiga F, Camafort M, Cepeda Rodrigo M, Diez-Manglano J, Pose Reino A, et al. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord. 2015;15:143.CrossRefPubMedPubMedCentral
19.
20.
Vogel T, Geny B, Kaltenbach G, Lang PO. Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants. Rev Med Interne. 2015;36(1):22–30.CrossRefPubMed
21.
Deschodt M, Flamaing J, Rock G, Boland B, Boonen S, Milisen K. Implementation of inpatient geriatric consultation teams and geriatric resource nurses in acute hospitals: a national survey study. Int J Nurs Stud. 2012;49(7):842–9.CrossRefPubMed
22.
McCusker J, Bellavance F, Cardin S, Trepanier S, Verdon J, Ardman O. Detection of older people at increased risk of adverse health outcomes after an emergency visit: the ISAR screening tool. J Am Geriatr Soc. 1999;47(10):1229–37.CrossRefPubMed
23.
Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10(1):20–30.CrossRefPubMed
24.
Folstein MF, Robins LN, Helzer JE. The mini-mental state examination. Arch Gen Psychiatry. 1983;40(7):812.CrossRefPubMed
25.
Kaiser MJ, Bauer JM, Ramsch C, Uter W, Guigoz Y, Cederholm T, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging. 2009;13(9):782–8.CrossRefPubMed
26.
Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis. 2013;106(5):303–23.CrossRefPubMed
27.
Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292–301.PubMedPubMedCentral
28.
Kim DH, Pieper CF, Ahmed A, Colon-Emeric CS. Use and interpretation of propensity scores in aging research: a guide for clinical researchers. J Am Geriatr Soc. 2016;64(10):2065–73.CrossRefPubMedPubMedCentral
29.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.CrossRef
30.
The R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016.
31.
Brown JD, Shewale AR, Dherange P, Talbert JC. A comparison of oral anticoagulant use for atrial fibrillation in the pre- and post-DOAC Eras. Drugs Aging. 2016;33(6):427–36.CrossRefPubMed
32.
Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–84.CrossRefPubMed
33.
Shah RU, Rupp AB, Mowery D, Zhang M, Stoddard G, Deshmukh V, et al. Changes in oral anticoagulant treatment rates in atrial fibrillation before and after the introduction of direct oral anticoagulants. Neuroepidemiology. 2016;47(3–4):201–9.CrossRefPubMed
34.
Staerk L, Fosbol EL, Gadsboll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in Denmark. Sci Rep. 2016;6:31477.CrossRefPubMedPubMedCentral
35.
European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.CrossRef
36.
Garkina SV, Vavilova TV, Lebedev DS, Mikhaylov EN. Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol. 2016;13(9):807–10.PubMedPubMedCentral
37.
Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–23.CrossRefPubMed
38.
Averlant L, Ficheur G, Ferret L, Boule S, Puisieux F, Luyckx M, et al. Underuse of oral anticoagulants and inappropriate prescription of antiplatelet therapy in older inpatients with atrial fibrillation. Drugs Aging. 2017;34(9):701–10.CrossRefPubMed
39.
Ali A, Bailey C, Abdelhafiz AH. Stroke prevention with oral anticoagulation in older people with atrial fibrillation—a pragmatic approach. Aging Dis. 2012;3(4):339–51.PubMedPubMedCentral
40.
Ng KH, Hart RG, Eikelboom JW. Anticoagulation in patients aged >=75 years with atrial fibrillation: role of novel oral anticoagulants. Cardiol Ther. 2013;2(2):135–49.CrossRefPubMedPubMedCentral
Metadata
Title
Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS2 Score ≥ 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?
Authors
Séverine Henrard
Caroline Vandenabeele
Sophie Marien
Benoit Boland
Olivia Dalleur
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2017
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-017-0493-3

Other articles of this Issue 11/2017

Drugs & Aging 11/2017 Go to the issue

Leading Article

Optimization of Drug Prescription and Medication Management in Older Adults with Cardiovascular Disease

Review Article

The Potential of β-Hydroxy-β-Methylbutyrate as a New Strategy for the Management of Sarcopenia and Sarcopenic Obesity

Current Opinion

Recent Progress in the Pharmacotherapy of Alzheimer’s Disease

Original Research Article

Clinical Decision Support and Optional Point of Care Testing of Renal Function for Safe Use of Antibiotics in Elderly Patients: A Retrospective Study in Community Pharmacy Practice

Original Research Article

Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients

Review Article

Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits